Acute poisoning on the medical admissions unit

Shaun A Summers MRCP, Specialist Registrar in Acute Medicine
Paul A Glyne PhD MRCP, Consultant Physician and Intensivist
Division of Emergency Services, University College London Hospitals NHS Foundation Trust

Alcohol intoxication, deliberate medicinal overdoses and ingestion of (illegal) substances are common reasons for admission to emergency departments in the UK, particularly in inner city hospitals. The annual health and social costs of misuse of alcohol and illegal drugs in England and Wales are each estimated to be nearly £20 billion. One million people use ecstasy, cocaine or other class A drugs each year and more than 100,000 people are injecting drug users. Both alcohol and other problem drug use are associated with a range of harms and cause substantial morbidity and mortality.1 This review discusses problems related to the ingestion of selected toxins.

Alcohol intoxication

Ethanol (alcohol) is commonly used in the community. The short- and long-term consequences of overconsumption are well described in the medical literature. This article will concentrate on three other alcohols – ethylene glycol, methanol and isopropyl alcohol – which can produce fatal intoxication through the ingestion of relatively small doses. All three are associated with a high osmolar gap, while ethylene glycol and methanol are also associated with a high anion gap metabolic acidosis.

Ethylene glycol

Ethylene glycol (EG) is a common constituent of antifreeze and screen wash products. Antifreeze overdoses used to be a frequent method of (self) poisoning.

There has been a decline in cases presenting over the last decade, but recently a rise in the number of cases admitted to emergency departments and renal units has been observed – where delayed treatment has rendered patients dialysis-dependent. Acute EG intoxication is a medical emergency that can lead to serious neurological, cardiopulmonary and renal dysfunction; it may result in death, particularly if treatment is delayed.2

EG toxicity is characterised by severe metabolic acidosis, high anion gap, high osmolar gap and calcium oxalate crystals in the urine. Following ingestion, the peak serum concentration is reached in 1–4 hours (half-life 3 hours). EG causes intoxication but the accumulation of toxic metabolites is responsible for the potentially fatal acidosis and renal failure which characterises EG poisoning.

The sequence of clinical events occurs on the following timescale:

- Stage 1 (30 min–12 hours): depressive central nervous system (CNS) disturbances often similar to alcohol intoxication.
- Stage 2 (12–24 hours): metabolic acidosis and cardiopulmonary effects.
- Stage 3 (24–72 hours): acute renal failure.

Further delayed neurological disturbances including cranial nerve palsies and polyradiculopathy are rare but well reported. Neurological complications usually occur 10–14 days postingestion.

Methanol

Intoxication by methanol (wood alcohol) often presents non-specifically. Symptoms include weakness, nausea, headache and a feeling of intoxication. Of significant concern are the eye changes which are (relatively) specific to methanol intoxication. Initial observations may include decreased vision, mydriasis, decreased light reflex and
hyperaemia of the optic disk. Optic atrophy secondary to anoxia in watershed areas of the cerebral and distal optic nerve circulations can lead to blindness.³

Severe intoxication has a significant morbidity. In patients presenting with seizures, coma or an arterial pH below 7.0 mmol/l, mortality rates above 80% have been described.⁴

Treatment for ethylene glycol and methanol intoxication. Treatment options for EG and methanol intoxication include fomepizole (the first line option), ethanol and haemodialysis. They are effective in preventing the development of toxic metabolites if administered soon after ingestion.⁵

**Isopropyl alcohol**

Commercially, isopropyl alcohol (isopropylol) is a common constituent of cleaning solvents and is used as a rubbing alcohol.⁶ Unlike EG and methanol, it is the parent compound that is toxic not the metabolites. Even small doses can produce CNS pathology, ataxia, lethargy, coma and myocardial depression (hypotension and cardiac shock). The condition should be suspected in the presence of clinical symptoms, with a high osmolar gap and the absence of metabolic acidosis (or hyperglycaemia). Treatment is predominantly supportive although haemodialysis may be useful in selected cases.⁶

**MDMA (ecstasy)**

Ecstasy is the most common stimulant found in dance clubs and at raves. MDMA stimulates both the CNS and the sympathetic nervous system, mainly through the release of serotonin, dopamine and noradrenaline from presynaptic neurons. It blocks their reuptake inactivation through the inhibition of monoamine oxidase.

It is difficult to establish an accurate incidence of the side effect profile for MDMA ingestion, owing to a bias on the reporting of adverse effects. There exists only limited data and reporting on how commonly MDMA is ingested without complication. Common reported side effects of MDMA include tachycardia, hypertension, tremor, arrhythmias, mydriasis, parkinsonism and urinary retention.¹⁰

Far more serious side effects (including death) are reported if the ‘serotonin syndrome’ develops. This usually manifests with gross hyperpyrexia, severe hypotension, in part related to a direct rise in antidiuretic hormone, myoclonus and rigidity (often with elevated creatinine kinase).¹¹ End-organ damage, including rhabdomyolysis, renal failure, hepatic failure, adult respiratory distress syndrome and disseminated intravascular coagulopathy are described.¹²

Treatment of MDMA intoxication is predominantly supportive. With hyperpyrexia, active cooling is advised. Benzodiazepines are advocated as first line drugs to reduce agitation. Urinary acidification, which can increase urinary amphetamine excretion, is not recommended because of the possibility of renal myoglobin precipitation. Renal replacement therapy, liver support,
including transplantation and intubation for respiratory support, may be required.

**Gamma-hydroxybutyrate (liquid ecstasy)**

GHB is a derivative of the inhibitory neurotransmitter gamma-aminobutyric acid. It occurs naturally in the CNS and regulates sleep cycles, core temperature, memory and cerebral glucose metabolism. GHB and its precursor, gamma-butyrolactone (GBL) are emerging substances of abuse, in both the USA and Europe.

Use of GHB as an anaesthetic and also as a sleep aid in hospital was common in the 1960s. When used recreationally, GHB is reported to cause euphoria and increase sensuality and disinhibition. GHB intoxication has serious complications and is potentially fatal. Several clinical features appear to be typical of GHB/GBL intoxication: deep coma with sudden wakening, bradycardia, hypoventilation and agitation. In addition, vomiting, transient agitation, myoclonic jerking and seizure are well described.

GHB is metabolised very quickly: it can be detected for only eight hours in blood and 12 hours in urine. The median duration of symptoms is usually short (two hours) and coma rarely lasts longer than four hours.

Interestingly, in a Swiss epidemiological study of 141 patients with GHB/GBL intoxication, 86 patients (61%) presented comatose. Death is well described with GHB/GBL intoxication, even if taken without alcohol or other ‘drugs’. Significantly, there are no reported deaths in hospitalised patients, making GHB a very serious intoxication in the prehospital setting. The deaths are related to cardiorespiratory depression, loss of airway and injuries associated with diminished judgement.

**Flunitrazepam (Rohypnol)**

Flunitrazepam is a potent benzodiazepine, with very rapid onset. It is abused for its intoxicant and relaxant effects and has been used in ‘date rape’. The side effect profile is similar to that of other benzodiazepines and is dose-related. Somnolence, impaired psychomotor behaviour, confusion, amnesia, visual disturbances, hallucinations and respiratory depression are all described.

Chronic use of flunitrazepam can induce dependence.

**Ketamine (Ketalar, K, special K)**

Ketamine, a phencyclidine derivative, which acts through the inhibition of neuronal uptake of norepinephrine, dopamine, serotonin and glutamate activation, is used as a dissociative anaesthetic in the hospital setting. It became popular because it causes anaesthesia without respiratory depression, though the adverse effects are known to include vivid dreams and hallucinations post-anaesthetic. These have limited its medical use but made it popular amongst recreational drug users.

The effects of ingestion appear rapidly and last from 30–60 minutes. The short duration of action often leads to sequential dose-taking. Acute pharmacological side effects include tachycardia, hypertension, visual hallucinations and impaired cognitive function. Toxic effects of ketamine include hyperexcitability, severe agitation and paranoid psychoses and, rarely, respiratory depression.

**References**